ondasdechoque.org
PT-BR

Trapezius myofascial pain: shockwaves versus low-level laser · Randomized trial · 2018

How does shockwave compare with laser for trapezius muscle pain?

In this trial, resting pain fell by about 20 points on a 0–100 scale with three weekly shockwave sessions and with 15 laser sessions, and the groups ended close at 15 weeks. Pressure pain on the left side fell more with shockwave.

No clear difference between the groups
adults with trapezius muscle pain
61
shockwave sessions, one a week
3
weeks of follow-up
15

Good to know: Laser took 15 sessions; shockwave took 3.

Király M, Bender T, Hodosi K Rheumatol Int, 2018 · Read the paper ↗

How this study worked

Shockwave30 peopleLow-level laser31 people
People were assigned to the groups by lot. Each dot is one person.

What happened

Neck and shoulder pain at rest

0–100 pain scale · start, end of treatment and week 15

ShockwaveLow-level laser

Resting pain fell from about 48 to 25 out of 100 with shockwave and from about 46 to 22 with laser. The groups ended close.
Show the numbers
GroupStartWeek 3Week 15
Shockwave47.725.725.4
Low-level laser46.0625.1622.42

The treatment

Shockwave

Shockwave, once a week for 3 weeks

ShockwavesThe paper doesn’t say whether radial or focused
Sessions
3, one a week
Pulses
1,000 per area · twice: around the trigger point, then on it
Strength
1.5–2bar 0.25 mJ/mm² printed for both steps · 10 per second
Numbing
Not mentioned
Device
BTL-6000 SWT Topline Power
Everyone also got
No other physiotherapy during follow-up

Compared with: Low-level laser on 15 working days over three weeks

Settings are what each study used, not a prescription.

Who took part

61 adults, mostly women in their late 50s and early 60s, with trapezius muscle pain for at least 8 weeks, at a Hungarian hospital clinic.

Shockwave30 people
Low-level laser31 people

Side effects

The authors say there were no side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Adults from a Hungarian county teaching hospital rheumatology outpatient clinic (February 2016–September 2017) with trapezius myofascial pain by Simons criteria and neck/shoulder pain for at least 8 weeks. Laser group: 31 (27 women, mean age 62.62); shockwave group: 30 (27 women, mean age 57.26).

Low-level laser31randomized

31 randomized and treated; 1 lost to follow-up for non-compliance; all 31 analysed with last observation carried forward.

Shockwaves30randomized

30 randomized and treated; none lost; 30 analysed.

Pain at rest2 reported outcomes
01
Week 3 (end of treatment)

Pain at rest

100 mm visual analogue scale (VAS), rest pain mm on a 100 mm VAS

BaselineFollow-up
Low-level laser
25.16
Shockwaves
25.7
0100 mm on a 100 mm VAS
means
GroupnBaselineFollow-up
Low-level laser3146.06 (SD 18.02)25.16 (SD 18.63)
Shockwaves3047.7 (SD 20.75)25.7 (SD 25.56)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)1.03CI 95% -8.116 to 10.176p = 0.822

Laser versus shockwaves, change from week 0 to week 3

Unadjusted

-10.3Equal results 012.4

Resting pain fell by about 20 mm in both groups. The between-group differences were small with wide intervals crossing zero at week 3 (1.030; P=0.822) and week 15 (−1.345; P=0.840). The abstract calls the week-15 value a significant laser advantage and the Results text calls week 3 a significant shockwave advantage; Table 1 supports neither.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

02
Week 15 (3 months after treatment)

Pain at rest

100 mm visual analogue scale (VAS), rest pain mm on a 100 mm VAS

BaselineFollow-up
Low-level laser
22.42
Shockwaves
25.4
0100 mm on a 100 mm VAS
means
GroupnBaselineFollow-up
Low-level laser3146.06 (SD 18.02)22.42 (SD 21.39)
Shockwaves3047.7 (SD 20.75)25.4 (SD 22.67)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-1.345CI 95% -14.6 to 11.91p = 0.840

Laser versus shockwaves, change from week 0 to week 15

Unadjusted

-17.8Equal results 015.1

Resting pain fell by about 20 mm in both groups. The between-group differences were small with wide intervals crossing zero at week 3 (1.030; P=0.822) and week 15 (−1.345; P=0.840). The abstract calls the week-15 value a significant laser advantage and the Results text calls week 3 a significant shockwave advantage; Table 1 supports neither.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

Pressure pain, left trapezius4 reported outcomes
03
Week 3 (end of treatment)

Pressure pain, left trapezius

100 mm VAS at a standardized dolorimeter pressure (BASELINE) mm on a 100 mm VAS

BaselineFollow-up
Low-level laser
61.65
Shockwaves
46.73
0100 mm on a 100 mm VAS
means
GroupnBaselineFollow-up
Low-level laser3110061.65 (SD 24.7)
Shockwaves3010046.73 (SD 23.14)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)14.911CI 95% 2.641 to 27.182p = 0.018

Laser versus shockwaves, change from week 0 to week 3

Unadjusted

-3.3Equal results 030.4

Left trapezius: pain under the standardized pressure fell more with shockwaves, by 14.911 mm at week 3 (95% CI 2.641 to 27.182; P=0.018) and 17.190 mm at week 15 (4.326 to 30.055; P=0.010). The right side did not show this, which the authors attribute to chance or the small sample.

Analysis details and source

By design, baseline pressure was set where each patient reported maximal pain, so baseline VAS is 100 in both groups (no SD); later visits repeat the same pressure. Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

04
Week 15 (3 months after treatment)

Pressure pain, left trapezius

100 mm VAS at a standardized dolorimeter pressure (BASELINE) mm on a 100 mm VAS

BaselineFollow-up
Low-level laser
59.29
Shockwaves
42.1
0100 mm on a 100 mm VAS
means
GroupnBaselineFollow-up
Low-level laser3110059.29 (SD 21.65)
Shockwaves3010042.1 (SD 28.23)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)17.19CI 95% 4.326 to 30.055p = 0.010

Laser versus shockwaves, change from week 0 to week 15

Unadjusted

-3.6Equal results 033.7

Left trapezius: pain under the standardized pressure fell more with shockwaves, by 14.911 mm at week 3 (95% CI 2.641 to 27.182; P=0.018) and 17.190 mm at week 15 (4.326 to 30.055; P=0.010). The right side did not show this, which the authors attribute to chance or the small sample.

Analysis details and source

By design, baseline pressure was set where each patient reported maximal pain, so baseline VAS is 100 in both groups (no SD); later visits repeat the same pressure. Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

05
Week 3 (end of treatment)

Pressure pain, right trapezius

100 mm VAS at a standardized dolorimeter pressure (BASELINE) mm on a 100 mm VAS

BaselineFollow-up
Low-level laser
60.65
Shockwaves
56.57
0100 mm on a 100 mm VAS
means
GroupnBaselineFollow-up
Low-level laser3110060.65 (SD 21.6)
Shockwaves3010056.57 (SD 22.17)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)4.078CI 95% -7.135 to 15.292p = 0.470

Laser versus shockwaves, change from week 0 to week 3

Unadjusted

-9.8Equal results 018

Right trapezius: pain under the standardized pressure fell in both groups; the between-group differences (4.078 at week 3, 9.561 at week 15) had intervals crossing zero (P=0.470 and 0.135).

Analysis details and source

By design, baseline pressure was set where each patient reported maximal pain, so baseline VAS is 100 in both groups (no SD); later visits repeat the same pressure. Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

06
Week 15 (3 months after treatment)

Pressure pain, right trapezius

100 mm VAS at a standardized dolorimeter pressure (BASELINE) mm on a 100 mm VAS

BaselineFollow-up
Low-level laser
56.16
Shockwaves
46.6
0100 mm on a 100 mm VAS
means
GroupnBaselineFollow-up
Low-level laser3110056.16 (SD 21.17)
Shockwaves3010046.6 (SD 27.74)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)9.561CI 95% -3.056 to 22.179p = 0.135

Laser versus shockwaves, change from week 0 to week 15

Unadjusted

-6.1Equal results 025.2

Right trapezius: pain under the standardized pressure fell in both groups; the between-group differences (4.078 at week 3, 9.561 at week 15) had intervals crossing zero (P=0.470 and 0.135).

Analysis details and source

By design, baseline pressure was set where each patient reported maximal pain, so baseline VAS is 100 in both groups (no SD); later visits repeat the same pressure. Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

Neck disability2 reported outcomes
07
Week 3 (end of treatment)

Neck disability

Neck Disability Index (NDI) points

means
GroupnBaselineFollow-up
Low-level laser3115.55 (SD 6.09)10.51 (SD 7.28)
Shockwaves3016.08 (SD 7.58)10.38 (SD 6.9)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)0.66CI 95% -1.933 to 3.253p = 0.612

Laser versus shockwaves, change from week 0 to week 3

Unadjusted

-2.6Equal results 03.9

NDI improved by about 5–7 points in both groups. Between-group differences were 0.660 at week 3 (95% CI −1.933 to 3.253; P=0.612) and 1.072 at week 15 (−2.110 to 4.254; P=0.503). The abstract and Results text describe a significantly larger shockwave improvement, which these intervals do not show.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

08
Week 15 (3 months after treatment)

Neck disability

Neck Disability Index (NDI) points

means
GroupnBaselineFollow-up
Low-level laser3115.55 (SD 6.09)10.01 (SD 6.91)
Shockwaves3016.08 (SD 7.58)9.47 (SD 5.65)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)1.072CI 95% -2.11 to 4.254p = 0.503

Laser versus shockwaves, change from week 0 to week 15

Unadjusted

-2.9Equal results 05

NDI improved by about 5–7 points in both groups. Between-group differences were 0.660 at week 3 (95% CI −1.933 to 3.253; P=0.612) and 1.072 at week 15 (−2.110 to 4.254; P=0.503). The abstract and Results text describe a significantly larger shockwave improvement, which these intervals do not show.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

SF-36 Physical functioning2 reported outcomes
09
Week 3 (end of treatment)

SF-36 Physical functioning

SF-36, physical functioning domain points

means
GroupnBaselineFollow-up
Low-level laser3162.26 (SD 16.47)69.03 (SD 18.86)
Shockwaves3067.83 (SD 20.12)76.67 (SD 18.3)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-2.059CI 95% -9.044 to 4.926p = 0.558

Laser versus shockwaves, change from week 0 to week 3

Unadjusted

-10.7Equal results 06.6

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

10
Week 15 (3 months after treatment)

SF-36 Physical functioning

SF-36, physical functioning domain points

means
GroupnBaselineFollow-up
Low-level laser3162.26 (SD 16.47)69.84 (SD 18.46)
Shockwaves3067.83 (SD 20.12)77.89 (SD 19.19)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-2.419CI 95% -11.104 to 6.265p = 0.579

Laser versus shockwaves, change from week 0 to week 15

Unadjusted

-13.2Equal results 08.3

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

SF-36 Role limitation, physical2 reported outcomes
11
Week 3 (end of treatment)

SF-36 Role limitation, physical

SF-36, role limitation, physical domain points

means
GroupnBaselineFollow-up
Low-level laser3145.16 (SD 36.18)59.68 (SD 41.67)
Shockwaves3040 (SD 35.72)68.33 (SD 37.68)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-13.817CI 95% -31.549 to 3.915p = 0.124

Laser versus shockwaves, change from week 0 to week 3

Unadjusted

-35.8Equal results 08.2

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

12
Week 15 (3 months after treatment)

SF-36 Role limitation, physical

SF-36, role limitation, physical domain points

means
GroupnBaselineFollow-up
Low-level laser3145.16 (SD 36.18)56.45 (SD 41.32)
Shockwaves3040 (SD 35.72)70.83 (SD 37.18)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-19.543CI 95% -37.894 to 1.192p = 0.037

Laser versus shockwaves, change from week 0 to week 15

Unadjusted

-42.6Equal results 05.9

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

SF-36 Role limitation, emotional2 reported outcomes
13
Week 3 (end of treatment)

SF-36 Role limitation, emotional

SF-36, role limitation, emotional domain points

means
GroupnBaselineFollow-up
Low-level laser3162.35 (SD 40.18)63.43 (SD 39.76)
Shockwaves3059.99 (SD 41.43)73.32 (SD 36.52)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-12.259CI 95% -32.903 to 8.345p = 0.239

Laser versus shockwaves, change from week 0 to week 3

Unadjusted

-37.9Equal results 013.3

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

14
Week 15 (3 months after treatment)

SF-36 Role limitation, emotional

SF-36, role limitation, emotional domain points

means
GroupnBaselineFollow-up
Low-level laser3162.35 (SD 40.18)62.35 (SD 43.67)
Shockwaves3059.99 (SD 41.43)77.77 (SD 37.48)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-17.779CI 95% -40.18 to 4.622p = 0.118

Laser versus shockwaves, change from week 0 to week 15

Unadjusted

-45.6Equal results 010

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

SF-36 Energy/fatigue2 reported outcomes
15
Week 3 (end of treatment)

SF-36 Energy/fatigue

SF-36, energy/fatigue domain points

means
GroupnBaselineFollow-up
Low-level laser3160.19 (SD 18.95)66.29 (SD 16.53)
Shockwaves3053.17 (SD 19)66.5 (SD 16.3)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-7.237CI 95% -15.439 to 0.966p = 0.083

Laser versus shockwaves, change from week 0 to week 3

Unadjusted

-17.4Equal results 02.9

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

16
Week 15 (3 months after treatment)

SF-36 Energy/fatigue

SF-36, energy/fatigue domain points

means
GroupnBaselineFollow-up
Low-level laser3160.19 (SD 18.95)68.87 (SD 17.5)
Shockwaves3053.17 (SD 19)69.67 (SD 13.89)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-7.823CI 95% -17.432 to 1.787p = 0.109

Laser versus shockwaves, change from week 0 to week 15

Unadjusted

-19.7Equal results 04.1

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

SF-36 Emotional well-being2 reported outcomes
17
Week 3 (end of treatment)

SF-36 Emotional well-being

SF-36, emotional well-being domain points

means
GroupnBaselineFollow-up
Low-level laser3172.9 (SD 19.18)74.84 (SD 19.38)
Shockwaves3069.2 (SD 16.94)79.8 (SD 14.6)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-8.665CI 95% -15.375 to 1.954p = 0.012

Laser versus shockwaves, change from week 0 to week 3

Unadjusted

-17.5Equal results 04

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

18
Week 15 (3 months after treatment)

SF-36 Emotional well-being

SF-36, emotional well-being domain points

means
GroupnBaselineFollow-up
Low-level laser3172.9 (SD 19.18)74.84 (SD 20.11)
Shockwaves3069.2 (SD 16.94)77.47 (SD 14.72)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-6.331CI 95% -14.538 to 1.875p = 0.128

Laser versus shockwaves, change from week 0 to week 15

Unadjusted

-16.5Equal results 03.8

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

SF-36 Social functioning2 reported outcomes
19
Week 3 (end of treatment)

SF-36 Social functioning

SF-36, social functioning domain points

means
GroupnBaselineFollow-up
Low-level laser3173.39 (SD 20.61)81.05 (SD 17.93)
Shockwaves3072.5 (SD 17.8)82.5 (SD 17.25)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-2.339CI 95% -12.959 to 8.281p = 0.662

Laser versus shockwaves, change from week 0 to week 3

Unadjusted

-15.5Equal results 010.8

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

20
Week 15 (3 months after treatment)

SF-36 Social functioning

SF-36, social functioning domain points

means
GroupnBaselineFollow-up
Low-level laser3173.39 (SD 20.61)79.44 (SD 20.04)
Shockwaves3072.5 (SD 17.8)84.17 (SD 19.4)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-5.618CI 95% -15.542 to 4.306p = 0.262

Laser versus shockwaves, change from week 0 to week 15

Unadjusted

-17.9Equal results 06.7

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

SF-36 Bodily pain2 reported outcomes
21
Week 3 (end of treatment)

SF-36 Bodily pain

SF-36, bodily pain domain points

means
GroupnBaselineFollow-up
Low-level laser3150.64 (SD 15.07)62.82 (SD 19.93)
Shockwaves3044.5 (SD 20.12)63.17 (SD 17.26)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-6.489CI 95% -15.1 to 2.121p = 0.137

Laser versus shockwaves, change from week 0 to week 3

Unadjusted

-17.2Equal results 04.2

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

22
Week 15 (3 months after treatment)

SF-36 Bodily pain

SF-36, bodily pain domain points

means
GroupnBaselineFollow-up
Low-level laser3150.64 (SD 15.07)69.11 (SD 17.94)
Shockwaves3044.5 (SD 20.12)69.08 (SD 18.53)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-5.116CI 95% -16.704 to 4.472p = 0.252

Laser versus shockwaves, change from week 0 to week 15

Unadjusted

-19.2Equal results 07

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

SF-36 General health2 reported outcomes
23
Week 3 (end of treatment)

SF-36 General health

SF-36, general health domain points

means
GroupnBaselineFollow-up
Low-level laser3151.94 (SD 15.37)55.97 (SD 17.82)
Shockwaves3052.23 (SD 20.83)57.33 (SD 20.96)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-1.058CI 95% -7.649 to 5.513p = 0.747

Laser versus shockwaves, change from week 0 to week 3

Unadjusted

-9.2Equal results 07.1

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

24
Week 15 (3 months after treatment)

SF-36 General health

SF-36, general health domain points

means
GroupnBaselineFollow-up
Low-level laser3151.94 (SD 15.37)56.29 (SD 17.84)
Shockwaves3052.23 (SD 20.83)57.46 (SD 19.1)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean between-group difference in change from baseline (as printed)-2.078CI 95% -9.398 to 5.241p = 0.572

Laser versus shockwaves, change from week 0 to week 15

Unadjusted

-11.2Equal results 07

Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.

Analysis details and source

Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.

Patient-signed medication record1 reported outcome
25
Week 15 (3 months after treatment)

Took pain or muscle medication

Patient-signed medication record participants

Low-level laser8 / 31
Shockwaves5 / 30
REPORTED COMPARISON TESTp = 0.384

Laser versus shockwaves, proportion taking medication at week 15

Chi-square or Fisher exact test

Medication use was uncommon in both groups at every visit (week 3: 4/31 laser vs 7/30 shockwaves, P=0.389; week 15: 8/31 vs 5/30, P=0.384). Medication for more than a week: 0/31 laser vs 4/30 shockwaves at week 3 and 1/31 vs 3/30 at week 15 (P=0.354); the text says most medicated patients took it for under a week, which holds for the laser arm but not the shockwave arm.

Analysis details and source

Counts as printed in Table 3; the Medicine <1 week / >1 week rows have missing percentages for some cells.

Clinical palpation1 reported outcome
26
Week 15 (3 months after treatment)

Palpable muscle knot (myogelosis) present

Clinical palpation participants

Low-level laser6 / 30
Shockwaves7 / 26
REPORTED COMPARISON TESTp = 0.587

Laser versus shockwaves, proportion with myogelosis at week 15

Chi-square or Fisher exact test

Knots were present at baseline in 12/30 laser and 15/26 shockwave participants and at week 15 in 6/30 and 7/26 (P=0.587).

Analysis details and source

Table 3 uses denominators of 30 and 26 for this row, unlike the 31 and 30 analysed elsewhere; the paper does not explain the difference.

Patient impression of change1 reported outcome
27
Weeks 3 and 15

Patient impression of change

Qualitative finding

On a 4-grade Likert scale (1 significantly improved to 4 worsened), the text reports that 86.6% improved and 13.3% were unchanged in both groups after therapy and at week 15. Table 2 prints means of 2.00±0.52 and 1.73±0.69 (laser) and 1.73±0.69 and 1.90±0.61 (shockwaves) with between-group P values of 0.078 and 0.283.

Analysis details and source

Table 2 column headings (outcome measure 0, 1, 2) do not align clearly with these values, since impression was not rated at week 0; the visit for each mean is therefore uncertain and no numeric groups are charted.

How treatment was delivered
Device and modality

BTL-6000 SWT Topline Power; the Introduction describes energy produced by high-pressure air. The paper does not label it radial or focused.

Pulses, pressure and energy

1,000 impulses around the trigger point at 1.5 bar and 10 Hz, then 1,000 on the trigger point at 2 bar and 10 Hz, 15 mm head; energy density printed as 0.25 mJ/mm² for both steps.

Sessions

Once weekly for 3 weeks (3 sessions). Completion required at least 80% of sessions. Anesthesia not mentioned.

Comparator

Low-level laser (PR999 4 W scanning laser, Medical Italia) on 15 working days over 3 weeks: 2 minutes around the trigger point at 2000 Hz (800 mW), 3 J/cm², and 2 minutes on the trigger point at 5000 Hz (2000 mW), 9 J/cm². No other physiotherapy during follow-up; rescue medication was recorded.

Allocation and blinding

Computer-generated allocation by an independent technician, sealed opaque envelopes; testing investigator and statistician blinded; patients not blinded.

HARMS & TOLERABILITY

The authors state that no adverse events were noted or recorded and that patients reported no side effects. How adverse events were sought is not described; Table 3 cited for this statement reports medication use and myogelosis only.

LIMITS OF THE ANALYSIS

Author-reported: large SDs and non-homogeneous baseline values; subjective patient-completed measures; wide age range; small sample; follow-up of only 15 weeks; an 8-week minimum symptom duration that may be short.

Abstract and text versus table: the abstract reports significantly better neck function with shockwaves (CIs −1.933 to 3.253 and −2.110 to 4.254), significantly better change in all SF-36 domains, and a significant laser advantage in resting pain at week 15 (P=0.840); the Results text adds a significant shockwave advantage for resting pain at week 3 (P=0.822). Table 1 supports none of these statements.

Within Table 1, role limitation (physical) at week 15 (P=0.037; CI −37.894 to 1.192) and emotional well-being at week 3 (P=0.012; CI −15.375 to 1.954) pair a significant P value with an interval that includes zero; a sign may be missing from the upper limit, but the paper does not say. The direction of the between-group difference is not defined.

Statistical methods state both that missing data were imputed by last observation carried forward and that no intention-to-treat analysis was used; Figure 1 analyses all 31 laser patients despite one loss to follow-up. Mann–Whitney/t tests on change scores were used; no primary outcome or multiplicity correction is named in the article.

Registry check by the extractor: ClinicalTrials.gov NCT03436459 was first submitted on 11 February 2018, after the study ended in September 2017; it lists eight primary outcomes (rest pain, pressure pain, function and quality of life at weeks 3 and 15) and actual enrolment of 60, whereas the article reports 61 randomized.

Extractor: the arms differed in contact time (15 laser visits versus 3 shockwave visits) and mean age (62.62 versus 57.26 years); patients were unblinded to visibly different treatments, and the pain, function, quality-of-life and impression outcomes were patient-rated. Funding: none. Conflicts: none declared.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Author-reported: large SDs and non-homogeneous baseline values; subjective patient-completed measures; wide age range; small sample; follow-up of only 15 weeks; an 8-week minimum symptom duration that may be short.
  • Abstract and text versus table: the abstract reports significantly better neck function with shockwaves (CIs −1.933 to 3.253 and −2.110 to 4.254), significantly better change in all SF-36 domains, and a significant laser advantage in resting pain at week 15 (P=0.840); the Results text adds a significant shockwave advantage for resting pain at week 3 (P=0.822). Table 1 supports none of these statements.
  • Within Table 1, role limitation (physical) at week 15 (P=0.037; CI −37.894 to 1.192) and emotional well-being at week 3 (P=0.012; CI −15.375 to 1.954) pair a significant P value with an interval that includes zero; a sign may be missing from the upper limit, but the paper does not say. The direction of the between-group difference is not defined.
  • Statistical methods state both that missing data were imputed by last observation carried forward and that no intention-to-treat analysis was used; Figure 1 analyses all 31 laser patients despite one loss to follow-up. Mann–Whitney/t tests on change scores were used; no primary outcome or multiplicity correction is named in the article.
  • Registry check by the extractor: ClinicalTrials.gov NCT03436459 was first submitted on 11 February 2018, after the study ended in September 2017; it lists eight primary outcomes (rest pain, pressure pain, function and quality of life at weeks 3 and 15) and actual enrolment of 60, whereas the article reports 61 randomized.
  • Extractor: the arms differed in contact time (15 laser visits versus 3 shockwave visits) and mean age (62.62 versus 57.26 years); patients were unblinded to visibly different treatments, and the pain, function, quality-of-life and impression outcomes were patient-rated. Funding: none. Conflicts: none declared.
Research review

Source-linked critical reading

randomized trial

Reading depthMaterial consulted
Technical source record

Complete local PDF read (8 pages), including all body sections, Tables 1–3, Figure 1, funding, conflict statement and references; ClinicalTrials.gov record NCT03436459 checked for dates and outcomes. No supplement is referenced.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Single-centre randomized trial with concealed allocation and a blinded tester and statistician; 61 of 70 screened were randomized (31 laser, 30 shockwaves). Patients were not blinded. Registered as NCT03436459, but only after the study ended.

Participants and setting

Adults from a Hungarian county teaching hospital rheumatology outpatient clinic (February 2016–September 2017) with trapezius myofascial pain by Simons criteria and neck/shoulder pain for at least 8 weeks. Laser group: 31 (27 women, mean age 62.62); shockwave group: 30 (27 women, mean age 57.26).

Treatment

BTL-6000 SWT Topline Power shockwaves (a compressed-air device per the Introduction; the paper does not use the word radial), once weekly for 3 weeks: 1,000 impulses around the trigger point at 1.5 bar, 10 Hz, then 1,000 impulses on the trigger point at 2 bar, 10 Hz, 15 mm head; energy density printed as 0.25 mJ/mm² for both steps.

Comparison

Low-level laser (PR999 4 W scanning laser, Medical Italia) on 15 working days over 3 weeks: 2 minutes around the trigger point at 2000 Hz (800 mW), 3 J/cm², and 2 minutes on the trigger point at 5000 Hz (2000 mW), 9 J/cm². No other physiotherapy during follow-up; rescue medication was recorded.

Outcomes and timing

Resting pain (100 mm VAS), pain under a standardized dolorimeter pressure on each trapezius, Neck Disability Index, SF-36 domains, medication use, myogelosis and a 4-grade patient impression, at weeks 0, 3 and 15. No single primary outcome is named in the article.

What the results show

Resting pain, NDI and SF-36 scores improved in both groups. Between groups, resting pain (week 15: −1.345; 95% CI −14.600 to 11.910) and NDI (1.072; −2.110 to 4.254) showed no clear difference; left-trapezius pressure pain fell more with shockwaves (17.190 mm; 4.326 to 30.055) but right-side pressure pain did not. Only 2 of 16 SF-36 contrasts had P<0.05, each with a printed CI that includes zero. The abstract and text describe significant shockwave advantages for neck function and all SF-36 domains, and a significant laser advantage in week-15 resting pain; Table 1 does not show these.

Harms

The authors state that no adverse events were noted or recorded and that patients reported no side effects. How adverse events were sought is not described; Table 3 cited for this statement reports medication use and myogelosis only.

Limits and disclosures

Concealed computer randomization with a blinded tester and statistician, but patients were unblinded, outcomes are self-reported, and laser was given 15 times versus shockwaves 3 times. The abstract and text claim significant shockwave advantages in neck function and all SF-36 domains that Table 1 does not show, and two P values conflict with their intervals. Registered retrospectively (ClinicalTrials.gov first submitted February 2018, after completion). No funding; no conflicts declared.

Application to care

Results concern mainly women (mean ages 57 and 63 years in the two arms) with trapezius myofascial pain in a Hungarian rheumatology clinic, comparing this specific pneumatic shockwave regimen with a 15-session laser regimen. Most between-group contrasts were not statistically significant, with intervals wide enough to include moderate differences in either direction; they do not establish superiority of either treatment or results beyond 15 weeks.

What remains to be tested

A prospectively registered trial naming one primary outcome, with matched visit schedules or sham control, intention-to-treat analysis, defined effect direction, structured harms recording and longer follow-up.

THE ORIGINAL SOURCE

Read the original article.

Comparative study of shockwave therapy and low-level laser therapy effects in patients with myofascial pain syndrome of the trapezius.

Király M, Bender T, Hodosi K. · Rheumatol Int · 2018

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →